首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   30775篇
  免费   2579篇
  国内免费   614篇
耳鼻咽喉   233篇
儿科学   1271篇
妇产科学   774篇
基础医学   1729篇
口腔科学   884篇
临床医学   3481篇
内科学   6234篇
皮肤病学   398篇
神经病学   1351篇
特种医学   793篇
外国民族医学   1篇
外科学   2856篇
综合类   4206篇
预防医学   4415篇
眼科学   318篇
药学   2430篇
  36篇
中国医学   1392篇
肿瘤学   1166篇
  2024年   25篇
  2023年   846篇
  2022年   1316篇
  2021年   1957篇
  2020年   1883篇
  2019年   1664篇
  2018年   1626篇
  2017年   1275篇
  2016年   1110篇
  2015年   1083篇
  2014年   2330篇
  2013年   2203篇
  2012年   1879篇
  2011年   2017篇
  2010年   1607篇
  2009年   1540篇
  2008年   1432篇
  2007年   1464篇
  2006年   1056篇
  2005年   963篇
  2004年   743篇
  2003年   621篇
  2002年   425篇
  2001年   399篇
  2000年   286篇
  1999年   261篇
  1998年   195篇
  1997年   185篇
  1996年   163篇
  1995年   172篇
  1994年   162篇
  1993年   125篇
  1992年   138篇
  1991年   116篇
  1990年   92篇
  1989年   81篇
  1988年   57篇
  1987年   67篇
  1986年   48篇
  1985年   60篇
  1984年   58篇
  1983年   42篇
  1982年   39篇
  1981年   36篇
  1980年   29篇
  1979年   19篇
  1978年   22篇
  1977年   14篇
  1976年   16篇
  1975年   6篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
刘刚军    马丽    乔慧   《现代预防医学》2022,(24):4442-4445
目的 这项研究在于掌握宁夏农村地区学龄儿童卫生服务利用现状及卫生服务利用公平性的动态变化,为政府部门了解学龄儿童卫生服务利用情况提供数据支撑,为学龄儿童健康促进方案的科学发展提供基础依据。方法 利用“农村居民家庭卫生健康询问调查”2009年开始的基准数据,以及2011、2012、2015和2019年随访调查数据,最终选取年龄为7~12岁并且调查时在家常住(指在家居住时间≥0.5年)的学龄儿童作为本次研究对象。利用χ2检验对不同收入水平组间的率进行比较,使用集中指数(concentration index,CI)衡量不同收入水平群体间卫生服务利用公平性的变化。结果 两周就诊情况经趋势χ2检验显示不同调查年份之间差异有统计学意义(χ2 = 16.189,P = 0.004);χ2检验显示,不同收入水平的人群在2011年(χ2 = 13.416,P = 0.028)、2012年(χ2 = 22.489,P = 0.009)存在统计上的显著差异。其他四年CI均为正值,只有2011年CI为负值,但是比较五次调查CI的绝对值,可以发现其保持下降。两周患病未就诊情况经趋势χ2检验显示不同调查年份之间差异有统计学意义(χ2 = 4.905,P = 0.027)。CI值均为负值,并且绝对值表现为下降态势,不公平程度正在减弱。住院情况经趋势χ2检验显示不同调查年份之间差异没有统计学意义(χ2 = 0.047,P = 0.829)。CI值均为正值,说明卫生服务利用偏向于高收入人群,绝对值整体上是下降的,表现为齿状波动样。结论 在农村学龄儿童中,卫生服务利用水平较低,五次调查发现不公平程度正在逐渐减小。  相似文献   
2.
目的研究2型糖尿病(T2DM)患者发生慢性肾脏病(CKD)的危险因素,并着重分析肥胖与CKD发生的关系。方法纳入2009年1月至2019年6月在南京鼓楼医院就诊的18至75岁诊断为T2DM的患者,收集一般资料包括性别、年龄、体重指数(BMI)、收缩压、舒张压、糖尿病病程以及实验室指标包括血红蛋白(Hb)、白蛋白、丙氨酸转氨酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、尿酸、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、尿白蛋白/肌酐比值和估算的肾小球滤过率。肥胖定义为BMI≥28 kg/m2,超重定义为24 kg/m2≤BMI<28 kg/m2。根据是否合并CKD,将研究对象分为合并CKD组和不合并CKD组。在不合并CKD的T2DM患者中,选取至少随访一次,随访时间超过12个月且随访数据完整的患者,按是否发生CKD分为发生CKD组和未发生CKD组。两组间各指标的比较采用t检验、非参数检验以及χ2检验。采用单因素及多因素logistic回归分析法分析T2DM患者发生CKD的危险因素,采用Cox比例风险模型分析随访的T2DM患者CKD发生的危险因素。采用限制性立方样条(RCS)拟合Cox回归模型来评估不同的BMI截点与CKD的关系。结果共纳入3194例T2DM患者,其中合并CKD组620例,不合并CKD组2574例。与不合并CKD组相比,合并CKD组T2DM患者BMI明显增高(P=0.005)。单因素logistic回归分析结果显示,性别、肥胖、收缩压、舒张压、Hb、白蛋白、TG、TC、FPG及HbA1c为T2DM患者发生CKD的影响因素(均P<0.05),将上述指标作为自变量,进行多因素logistic回归分析,结果显示,肥胖(OR=1.058,95%CI 1.079~2.018),收缩压增高(OR=1.027,95%CI 1.018~1.035),TG增加(OR=1.087,95%CI 1.008~1.171),FPG增高(OR=1.042,95%CI 1.003~1.083)是T2DM患者发生CKD的影响因素(均P<0.05)。不合并CKD组中随访时间超过12个月且随访数据完整的T2DM患者共753例,其中,发生CKD组182例,未发生CKD组571例。Cox比例风险模型分析结果显示,在校正年龄、糖尿病病程、收缩压、AST、TG及FPG后,超重为发生CKD的危险因素(OR=1.95,95%CI 1.05~3.61)。RCS拟合Cox回归模型结果显示,T2DM患者BMI与CKD发生风险呈非线性关系,BMI在28~31 kg/m2的T2DM患者CKD的发生风险增加(均P<0.05)。结论T2DM患者肥胖与CKD密切相关,肥胖的T2DM患者,特别是BMI在28~31 kg/m2,容易发展为CKD。  相似文献   
3.
4.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals.  相似文献   
5.
目的探讨针刺联合中药熏蒸对踝关节骨折术后患者踝关节功能及骨代谢指标的影响。方法以沈阳市第一人民医院收治的110例接受手术治疗的踝关节骨折患者作为研究对象,随机分为对照组和试验组,各55例。对照组给予常规康复训练,试验组在此基础上应用针刺联合中药熏蒸治疗,治疗3个月。比较两组总体疗效,观察两组踝关节量表(Olerud-Molander、Baird)评分变化情况、踝关节功能包括踝关节肌力和关节主动活动度以及骨代谢指标改善情况。结果试验组优良率高于对照组(70.91%vs.43.63%,P<0.05)。治疗后,两组患者Baird踝关节评分、Olerud-Molander功能评分均明显升高(P<0.05);踝关节肌力和关节主动活动度均提升(P<0.05);骨代谢指标血清骨钙素(BGP)、前胶原氨基端肽(PINP)、前胶原羧基端肽(PICP)、血清总骨Ⅰ型前胶原氨基端延长肽(Total-PINP)和Ⅰ型胶原羧基端肽β特殊序列(β-CTX)水平降低(P<0.05);试验组各指标改善均优于对照组(P<0.05)。结论针刺联合中药熏蒸具有活血止痛、化瘀消肿、补肾壮骨之效,作用于踝关节骨折术后患者,可有效恢复其踝关节功能,缓解关节疼痛、肿胀症状,调节骨代谢指标,对于踝关节骨折术后有较好的治疗效果。  相似文献   
6.
This study investigated the role of dual-energy computed tomography (CT) for lesion characterization in patients with peripheral arterial disease manifesting with chronic total occlusions (CTOs). Forty-one symptomatic patients with CTOs underwent dual-energy CT angiography before endovascular treatment. The lesions were subsequently analyzed in a dedicated workstation, and 2 indexes—dual-energy index (DEI) and effective Z (Zeff)—were calculated, ranging from 0.0027 to 0.321 and from 6.89 to 13.02, respectively. Statistical analysis showed a significant correlation between the DEI and Zeff values (P < .001). The interobserver intraclass correlation coefficient was 0.91 for the mean Zeff values and 0.86 for the mean DEI values. This technique could potentially provide useful information regarding the composition of a CTO.  相似文献   
7.
ObjectivesRecurrent Aphthous Stomatitis (RAS) a chronic idiopathic oral mucosal disease. But yet the etiology and pathogenesis of RAS are not exactly known, it is thought that inflammation play an important role in the pathogenesis. The aim of this study is to demonstrate the role of systemic inflammation among the possible etiological factors of RAS and to find the possible diagnostic correlation between Systemic Immune Inflammation Index (SII).MethodsPatients who were consulted the otolaryngology outpatient clinic and diagnosed with RAS between 2019–2021 were retrospectively analyzed. Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and SII values were calculated based on the results of complete blood count. Demographic and hematological parameters between control and RAS groups were compared. The statistical significance level was considered as <0.05.ResultsThere was no statistically significant difference between the control and RAS groups in terms of sex and age distributions (p = 0.566 and p = 0.173, respectively). SII, NLR and PLR values were significantly higher in the RAS group compared to the controls (p < 0.001, p < 0.001 and p = 0.001, respectively). A very strong correlation between SII and NLR, moderately strong correlation between SII and PLR and moderate correlation between NLR and PLR values were detected (respectively ρ: 0.813, 0.719, 0.532; p-values <0.001).ConclusionSII, NLR and PLR has significantly higher levels in the RAS group compared to the control group, that it supports the role of systemic inflammation in the etiopathogenesis of RAS. In addition, the results show that SII is a valuable marker for inflammation.Level of evidence4.  相似文献   
8.
目的 探讨儿童哮喘风险评分(PARS)和哮喘预测指数(API)对反复喘息幼儿发生支气管哮喘(哮喘)的预测价值,为儿童哮喘的精准预测提供充分的证据。方法 收集100例1~3岁反复喘息儿童的临床资料,分别进行PARS和API评估,随访观察患儿是否发生哮喘,比较两者单独或联合应用的预测效能。结果 PARS预测反复喘息幼儿发生哮喘的灵敏度和特异度分别为54.55%和86.52%,ROC AUC为0.744 (95% CI 0.578~0.909)。API预测反复喘息幼儿发生哮喘的灵敏度和特异度分别为72.73%和52.81%,ROC曲线下面积为0.628(95% CI 0.460~0.796)。两者联合预测反复喘息幼儿发生哮喘的灵敏度和特异度分别为81.82%和44.94%,ROC曲线下面积为0.634(95% CI 0.474~0.794)。PARS预测反复喘息幼儿发生哮喘的ROC AUC略高于API及联合检测,但组间比较差异均无统计学意义(P均>0.05)。结论 PARS和API用于预测反复喘息幼儿发生哮喘的临床价值相当。  相似文献   
9.
10.
ObjectiveTo determine the long-term cardiovascular disease risk of astronauts with spaceflight exposure compared with a well-matched cohort.MethodsNational Aeronautics and Space Administration (NASA) astronauts are selected into their profession based upon education, unique skills, and health and are exposed to cardiovascular disease risk factors during spaceflight. The Cooper Center Longitudinal Study (CCLS) is a generally healthy cohort from a preventive medicine clinic in Dallas, Texas. Using a matched cohort design, astronauts who were selected beginning April 1, 1959, (and each subsequent selection class through 2009) and exposed to spaceflight were matched to CCLS participants who met astronaut selection criteria; 1514 CCLS participants matched to 303 astronauts in a 5-to-1 ratio on sex, date of birth, and age. The outcome of cardiovascular mortality through December 31, 2016, was determined by death certificate or National Death Index.ResultsThere were 11 deaths caused by cardiovascular disease (CVD) among astronauts and 46 among CCLS participants. There was no evidence of increased mortality risk in astronauts (hazard ratio [HR]=1.10; 95% confidence interval [CI], 0.50 to 2.45) with adjustment for baseline cardiovascular covariates. However, the secondary outcome of CVD events showed an increased adjusted risk in astronauts (HR=2.41; 95% CI, 1.26 to 4.63).ConclusionNo increased risk of CVD mortality was observed in astronauts with spaceflight exposure compared with a well-matched cohort, but there was evidence of increased total CVD events. Given that the duration of spaceflight will increase, particularly on missions to Mars, continued surveillance and mitigation of CVD risk is needed to ensure the safety of those who venture into space.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号